Limited ESA Use in COVID-19 Patients Recommended
Anemia in patients hospitalized with COVID-19 can be severe, but in most cases, clinicians should limit their use of erythropoiesis-stimulating agents.
Hematologic Disorders
Tazverik Granted Accelerated Approval for Follicular Lymphoma
Tazverik, a methyltransferase inhibitor, is already indicated for the treatment of patients aged ≥16 years with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Blood Donors Will Get Results of Coronavirus Antibody Test, Red Cross Says
Positive test result does not confirm immunity to the virus, and test is not meant to diagnose illness.
Biosimilar Nyvepria Gets FDA Approval
The Food and Drug Administration (FDA) has approved Nyvepria™ (pegfilgrastim-apgf; Pfizer), a biosimilar to Neulasta (pegfilgrastim; Amgen). Nyvepria, a leukocyte growth factor, is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. The approval…
FDA Grants Orphan Drug Status to Mitapivat for Thalassemia
The FDA has granted Orphan Drug designation to mitapivat (AG-348; Agios Pharmaceuticals) for the treatment of thalassemia.
Mepolizumab Gets Priority Review for Hypereosinophilic Syndrome
The FDA previously granted Fast Track and Orphan Drug designations to mepolizumab for the treatment of HES.
Ferriprox Twice-a-Day Tablet Dosing Approved for Transfusional Iron Overload Due to Thalassemia Syndromes
The FDA has approved a twice-a-day formulation of Ferriprox® (deferiprone; Chiesi) for the treatment of transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.
Sutimlimab Under Review for Hemolysis in Cold Agglutinin Disease
The FDA has granted Priority Review for the Biologics License Application (BLA) for sutimlimab for the treatment of hemolysis in adult patients with cold agglutinin disease, a rare type of autoimmune hemolytic anemia.
Successful Management of Severe COVID-19 in Otherwise Healthy Pediatric Patient
Sustained improvement was noted after the administration of tocilizumab, an interleukin-6 antagonist.
Vadadustat Noninferior to Darbepoetin Alfa for Anemia in Patients With Dialysis-Dependent CKD
The studies compared the efficacy and safety of vadadustat to darbepoetin alfa in adult patients on dialysis with anemia due to CKD.
